::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

METABOLIC SYNDROME IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN PAKISTAN

AUTHORS:

Dr Maha Arshad, Dr Haroon Ashraf, Dr Sobia Abbas

ABSTRACT:

Introduction: Chronic bronchitis is defined as a chronic productive cough for three months in each of two successive years in a patient in whom other causes of chronic cough (eg, bronchiectasis) have been excluded. It may precede or follow development of airflow limitation. Objectives of the study: The basic aim of the study is to find the analysis of metabolic syndrome in patients with Chronic Obstructive Pulmonary Disease in Pakistan. Methodology of the study: This cross sectional study was conducted at LMDC during June 2019 to December 2019. This was basically a cross sectional study and sample size was 148. After approval from ethical committee all the parents were informed for the purpose of the study and a written informed consent was taken from the patients. Results: From 148 patients, it was observed that the minimum age was 36 years and maximum age was 65 years with mean and standard deviation of the age was 52.44 ± 7.83 years. The minimum glucose level was 80 mg/dL and maximum was 115 mg/dL with mean and standard deviation was 94.05 ± 11.15 mg/dL. The minimum triglyceride level was 100 mg/dL and maximum was 370 mg/dL with mean and standard deviation was 181.70 ± 88.03 mg/dL. The minimum High Density Lipoprotein level was 30 mg/dL and maximum was 58 mg/dL with mean and standard deviation was 46.22 ± 9.03 mg/dL. Conclusion: The frequency of metabolic syndrome was found in 43.9% patients with chronic obstructive pulmonary disease. All effect modifiers have significant influence.